Clinical trial
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic…
NCT00036257 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00036257 |
|---|---|
| Title | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Cell Pathways Industry OSI Pharmaceuticals |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | CP-461 |
| Enrollment | 15 |
| Start date | Mar 1, 2002 |
| Completion | Apr 1, 2003 |
| First posted | May 9, 2002 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: